Search

Your search for "odyy" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

August 18, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

August 16, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview

August 11, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, is sharing an interview by NFL Hall of Famer Brett Favre. During the interview, hosted by Bubba, the Love Sponge(R), Favre talks about the many concussions he received […]

News Articles

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers Odyssey Health recently announced a redesign of its website […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial

August 10, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Dr. Jacob VanLandingham, Brett Favre Featured in ‘Get Authentic’ Podcast

August 9, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent episode of Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Unveils New Corporate Website

August 4, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various […]

News Articles

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits Another long-standing concern among service personnel is the treatment of concussive brain injuries Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health […]

News Articles

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

August 1, 2022

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to age Odyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dedicating Strategy Toward Acquisition, Creation of Lifesaving Medical Products

July 28, 2022

Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild […]

News Articles

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of players Currently, there is no FDA-approved medicinal treatment for helping people with concussion injuries Odyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injury Retired pro soccer and football athletes […]

News Articles

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

July 26, 2022

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billion Odyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussions Once approved, Odyssey is confident that PRV-002 will […]

News Articles

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

July 22, 2022

Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments  The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

July 20, 2022

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a […]

News Articles

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

July 14, 2022

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., will be featured in a new interview aired by RedChip Companies on The RedChip Money Report(R) on Bloomberg TV at 7 p.m. Eastern Time this Saturday, July 16. Bloomberg TV is available in an estimated 73 million homes across the U.S. In the exclusive interview, Odyssey […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast Spotlighting Two-Time Olympic Gold Medalist Abby Wambach

July 13, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest episode of InvestorBrandNetwork’s Stock2Me podcast. Hosted by Stuart Smith, the podcast talks with soccer play Abby Wambach, an Olympic gold medalist and member of ODYY’s sports advisory board. During the interview, Wambach […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Single Ascending Dosing for Intranasal Concussion Drug

July 12, 2022

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in its Phase I Single Ascending Dosing (“SAD”) clinical trial. According to the update, Odyssey’s trial involves administering PRV-002, the company’s novel drug to treat concussion, to healthy human […]

News Articles

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

July 11, 2022

Odyssey’s Sports Advisory Board (“SAB”) was formed in 2021 to enhance public awareness of traumatic brain injuries and concussion The board’s members – Abby Wambach, Kurt Warner, and Brett Favre – have had storied careers in their respective sports and have expressed hope that scientists will examine their brains after their death to advance their […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Poised to Successfully Commercialize Its Products

July 7, 2022

Odyssey Health (OTC: ODYY) is a Nevada-based medical company developing a variety of drug and technology assets to treat unmet clinical needs. “Odyssey is dedicated to advancing life-saving medical products that offer similar levels of hope to a new generation of people through technological and clinical developments that demonstrate advantages over current standards of care. […]

News Articles

Odyssey Health, Inc. (ODYY) Optimistic About Drug/Tech IP as Industry Studies Big Pharma M&A Outlook

July 6, 2022

Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare […]

News Articles

Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions

July 1, 2022

No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002  Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients The CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Completes Safety Evaluation of Cohort II for Novel Drug to Treat Concussion

June 29, 2022

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from cohort II of its phase I clinical trial. According to the update, the trial involves administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. Cohort II data indicates […]

News Articles

Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug

Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion Currently, concussions do not have an FDA-approved treatment Soldiers form a significant population of people who frequently experience multiple concussions throughout their career Concussion has only recently received greater attention as different parties seek […]

News Articles

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

June 27, 2022

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantage The company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device  Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussion […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Sets Sights on US Phase II Clinical Trials with Focus on Military

June 24, 2022

Odyssey Health (OTC: ODYY) understands the severity of concussions among service members as well as the existing gaps in treatment. The Center for Disease Control (“CDC”) reports that over 430,000 military service members were diagnosed with traumatic brain injury (“TBI”) between 2000 and 2020, with 75-83% of the cases being categorized as mild (“mTBI”) or […]

News Articles

Odyssey Health, Inc. (ODYY) Interview Addresses Company’s Focus on Development of Drug and Device Technologies to Treat Unmet Medical Needs

June 21, 2022

Odyssey Group International Inc. is a Nevada based medical company developing a variety of drug and technology assets to treat unmet clinical needs Odyssey CEO Michael Redmond recently appeared on Bloomberg TV’s The RedChip Money Report(R) to discuss the development pipeline for three of the company’s four products and pending clinical testing Odyssey’s assets include […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Novel Drug Candidate Represents a Valuable Asset

June 15, 2022

Odyssey Health (OTC: ODYY) recently completed a safety evaluation of cohort I of its phase I clinical trial administering PRV-002, the company’s novel drug treatment for concussion. “Findings from the cohort, which included eight healthy human volunteers that received a single dose of PRV-002 or placebo followed by evaluations for abnormal responses, showed that the […]

News Articles

Odyssey Health, Inc. (ODYY) Moving to Fill Gaps in Treatment and Management of Concussion Among Military Service Members

June 14, 2022

Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concussion” Although concussion greatly impacts the military, there are significant gaps in the understanding of the optimal […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) CEO Spotlighted in RedChip Money Report Interview

June 9, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmond is slated for broadcast at 7 p.m. ET on June 11. During […]

News Articles

Odyssey Health, Inc. (ODYY) Marks New Milestone in Pursuit of Concussion Treatment with Positive Safety Findings from Cohort I of Phase 1 Clinical Trial for PRV-002

June 8, 2022

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs The subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has no FDA-approved drug Data from Cohort I of the Phase I study showed […]

InvestorNewsBreaks

InvestorNewsBreaks – Why Odyssey Health Inc. (ODYY) Is ‘One to Watch’

June 7, 2022

Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems, and forging strategic partnerships, the company boasts a diverse development portfolio spanning both […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Safety Findings from Clinical Trial of Concussion Drug

June 1, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety evaluation for cohort 1 of its phase 1 clinical trial, which is being conducted by Nucleus Network, a leading clinical research organization. The trial studies the treatment of concussions in healthy human subjects […]

News Articles

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

May 31, 2022

Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from Phase I Clinical Trial for Novel Drug to Treat Concussion

May 9, 2022

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human […]

News Articles

Odyssey Group International Inc. (OTCQB: ODYY) Featured in Virtual Coverage of Investor Summit Group’s Q1 Virtual Summit

March 22, 2021

Odyssey Group International Inc. (OTCQB: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey’s corporate mission is to create, acquire and accumulate distinct assets, intellectual properties and exceptional technologies that provide meaningful medical solutions. The company is focused on building and acquiring assets in […]

Press Releases

IBN (InvestorBrandNetwork) Announces ‘Dr. Finance Live’ Interview with NFL Hall of Famer Brett Favre and Odyssey Health Inc.’s Dr. Jacob VanLandingham

August 16, 2022

LOS ANGELES, Aug. 16, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN, a multifaceted financial news and publishing company for private and public entities, today announces that NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, Head of Drug Development for medical technology company Odyssey Health Inc. (OTC: ODYY), recently appeared on Dr. Finance Live, a podcast series focused […]

Press Releases

IBN (InvestorBrandNetwork) Announces ‘Get Authentic’ Interview with NFL Hall of Famer Brett Favre and Odyssey Health Inc.’s Dr. Jacob VanLandingham

August 9, 2022

LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) — via InvestorWire — IBN, a multifaceted financial news and publishing company for private and public entities, today announces that NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, Head of Drug Development for medical technology company Odyssey Health Inc. (OTC: ODYY), recently appeared on Get Authentic with Marques Ogden, a podcast […]

Press Releases

IBN (InvestorBrandNetwork) Announces Latest Episode of The Stock2Me Podcast featuring Two-Time Olympic Gold Medalist Abby Wambach on Behalf of Odyssey Health Inc.

July 13, 2022

LOS ANGELES, July 13, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).